Catalyst Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Catalyst Pharmaceuticals Inc in the first quarter 2026?
Catalyst Pharmaceuticals Inc achieved a return on average equity (ROE) of 23.65 % in its first quarter 2026, this is above CPRX's average return on equity of -11.07%.
Catalyst Pharmaceuticals Inc shareholder's equity over the 12 months ending in its first quarter 2026 are valued at $936 million

ROE fell compared to the fourth quarter 2025, despite the net income growth of 20.94% from the fourth quarter 2025.

Within the Major Pharmaceutical Preparations industry 32 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 341 to 386.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Equity Change	27.5 %	31.15 %	39.23 %	40.64 %	-
Y / Y Net Income Change	12.33 %	-5.79 %	20.28 %	27.73 %	143.77 %
Net Income (TTM) in Millions	221	214	218	209	197
Return On Equity (TTM)	23.65 %	24.32 %	26.39 %	27.47 %	28.28 %
CPRX's Total Ranking	# 386	# 341	# 405	# 342	# 356
Equity (TTM) in Millions	1,013	954	920	856	794
Seq. Equity Change	6.12 %	3.7 %	7.5 %	7.77 %	9.16 %
Seq. Net Income Change	20.94 %	-0.16 %	1.3 %	-8.16 %	1.43 %

Back to CPRX Management Effectiveness >> CPRX's 5 Years Annual ROE >> Compare CPRX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 33
Sector	# 72
Overall	# 386

Return On Equity Statistics
High	Average	Low
62.82 %	-11.07 %	-115.92 %
(Sep 30 2020)		(Jun 30 2012)

CPRX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	954	728	388	300	207
Y / Y Equity Change	31.15 %	87.59 %	29.11 %	45.25 %	21.95 %
Net Income in Millions	214	164	71	83	39
Y / Y Net Income Change	30.78 %	129.5 %	-14.05 %	110.42 %	-47.35 %
Return On Equity	22.46 %	22.52 %	18.41 %	27.65 %	19.09 %

Back to CPRX Management Effectiveness >> CPRX's 5 Years Annual ROE >> Compare CPRX ROE to its Competitors

Annual Roe Comment

In 2025 ROE fell to 22.46 %, despite net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CPRX's' Return on Equity at Yahoo Finance
CPRX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CPRX's Competitors
Subscribers only: Roe for Catalyst Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for CPRX's Customers

Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector	ROE
Aurinia Pharmaceuticals Inc	64.48 %
Lifemd Inc	63.70 %
Zoetis Inc	61.63 %
Vaxart Inc	61.43 %
Dariohealth Corp	60.52 %
Nrc Health	57.25 %
Oramed Pharmaceuticals Inc	55.40 %
Innoviva Inc	47.59 %
Concentra Group Holdings Parent Inc	46.95 %
Liquidia Corporation	46.82 %
Agilent Technologies inc	44.45 %
Tenet Healthcare Corp	44.20 %
Theravance Biopharma inc	43.85 %
Gilead Sciences Inc	42.33 %
Transmedics Group Inc	41.92 %
Abeona Therapeutics Inc	41.40 %
Apellis Pharmaceuticals Inc	39.71 %
Adma Biologics Inc	38.97 %
Bristol myers Squibb Company	38.94 %
Acadia Pharmaceuticals Inc	35.65 %
Spero Therapeutics Inc	35.58 %
Illumina Inc	33.99 %
Dexcom Inc	33.83 %
Rafael Holdings Inc	31.93 %
Solventum Corporation	30.71 %
Phibro Animal Health Corporation	30.60 %
Pro dex Inc	30.01 %
Incyte Corporation	29.20 %
Protalix Biotherapeutics inc	28.10 %
Collegium Pharmaceutical Inc	26.74 %

Date modified: 2026-06-22T14:32:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.